Riassunto
In questo articolo presenteremo le nuove prospettive terapeutiche nel diabete di tipo 2 che si sono concretizzate negli ultimi anni. L’attenzione sarà rivolta ai nuovi farmaci dotati di attività insulino-stimolante, come la glimepiride, un derivato sulfonilureico, e la repaglinide, un derivato dell’acido benzoico. Verrà quindi esaminata una nuova categoria di farmaci, i tiazolidinedioni, che esercitano il loro effetto migliorando l’azione dell’insulina, in genere compromessa nel diabete di tipo 2. Verrà fatto un cenno allo stato attuale degli inibitori delle α-glicosidasi, ormai da qualche anno entrati nell’uso clinico. Infine, verrano presentate le prospettive terapeutiche future.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837, 1998.
Kramer W, Muller G, Geisen K. Characterization of the molecular mode of action of the sulphonylurea, glimepiride, at the beta cells. Horm Metab Res 28: 464, 1996.
Drager KE, Wernicke-Panten K, Lamp H-J, Schuler E, Roskamp R. Long-term treatment of type 2 diabetic patients with new oral antidiabetic agent glimepiride 4 (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 28: 419, 1996.
Massi Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 28: 451, 1996
Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulphonylureas and glimepiride. Horm Metab Res 28: 496, 1996.
Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47: 345, 1998.
Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22: 789, 1999.
Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter JD, Moffitt P, Hopkin H. Effect of repaglinide addition to metformin monotherapy on patients with type 2 diabetes. Diabetes Care 22: 119, 1999.
Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alfa-induced inhibition of insulin signaling. J Clin Invest 100: 1863, 1997.
Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 26: 553, 1997.
Sehoonjani K, Avwerx J. Thiazolidinediones: an update. Lancet 355: 1008, 2000.
Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus. Drug Safety 11: 432, 1994.
Carrascosa M, Pascual F, Aresti S. Acarbose-induced acute severe hepatotoxicity. Lancet 349: 698, 1997.
Shinkai H, Sato Y. Hypoglycemic action of phenylalanine derivatives. In: Bailey CJ, Flatt PR (Eds.) New antidiabetic drugs. Smith-Gordon, London, UK, p 249, 1990.
Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic C. Antidiabetogenic effects of glucagon-like peptide-l (7–36 amide) in normal subjects and in patients with diabets mellitus. N Engl J Med 326: 1316, 1992.
Kolterman OG, Gottlieb AB, Organ KA, Thompson RG. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amilin analogue. Diabetes Care 18: 1179, 1995.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Santeusanio, F., Perriello, G. Nuovi farmaci per la terapia del diabete di tipo 2. L’Endocrinologo 1, 15–22 (2000). https://doi.org/10.1007/BF03344365
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344365